Update of pathophysiology and management of diabetic kidney disease

Gross, 2005, Diabetic nephropathy: diagnosis, prevention, and treatment, Diabetes Care, 28, 164, 10.2337/diacare.28.1.164 de Boer, 2011, Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort, Arch Intern Med, 171, 412, 10.1001/archinternmed.2011.16 Huang, 2012, Diabetes-related kidney, eye, and foot disease in Taiwan: an analysis of the nationwide data for 2000–2009, J Formos Med Assoc, 111, 637, 10.1016/j.jfma.2012.09.006 2014 Annual Report on Kidney Disease in Taiwan. http://www.tsn.org.tw/UI/H/2014ARKDT/2014_ARKDT_ch0.pdf. Mogensen, 1997, How to protect the kidney in diabetic patients: with special reference to IDDM, Diabetes, 46, S104, 10.2337/diab.46.2.S104 Retnakaran, 2006, Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74, Diabetes, 55, 1832, 10.2337/db05-1620 Melmed, 2015 Tuttle, 2017, Back to the future: glomerular hyperfiltration and the diabetic kidney, Diabetes, 66, 14, 10.2337/dbi16-0056 Potenza, 2009, Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets, Curr Med Chem, 16, 94, 10.2174/092986709787002853 de Zeeuw, 2014, The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy, J Am Soc Nephrol, 25, 1083, 10.1681/ASN.2013080830 Prabhakar, 2004, Role of nitric oxide in diabetic nephropathy, Semin Nephrol, 24, 333, 10.1016/j.semnephrol.2004.04.005 Bernhardt, 2006, Expression of hypoxia-inducible transcription factors in developing human and rat kidneys, Kidney Int, 69, 114, 10.1038/sj.ki.5000062 Resnick, 2003, Diabetes and sleep disturbances: findings from the Sleep Heart Health Study, Diabetes Care, 26, 702, 10.2337/diacare.26.3.702 Aronsohn, 2010, Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes, Am J Respir Crit Care Med, 181, 507, 10.1164/rccm.200909-1423OC Peppard, 2000, Prospective study of the association between sleep-disordered breathing and hypertension, N Engl J Med, 342, 1378, 10.1056/NEJM200005113421901 Leong, 2016, The association between obstructive sleep apnea on diabetic kidney disease: a systematic review and meta-analysis, Sleep, 39, 301, 10.5665/sleep.5432 Pallayova, 2014, Novel insights into metabolic sequelae of obstructive sleep apnoea: a link between hypoxic stress and chronic diabetes complications, Diabetes Res Clin Pract, 104, 197, 10.1016/j.diabres.2014.01.007 Tan, 2006, Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea, Sleep, 29, 329, 10.1093/sleep/29.3.329 Forbes, 2008, Oxidative stress as a major culprit in kidney disease in diabetes, Diabetes, 57, 1446, 10.2337/db08-0057 Phisitkul, 2008, Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy, Am J Med Sci, 335, 284, 10.1097/MAJ.0b013e318156b799 Ziyadeh, 2008, Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy, Curr Diabetes Rev, 4, 39, 10.2174/157339908783502370 Wada, 2016, Innate immunity in diabetes and diabetic nephropathy, Nat Rev Nephrol, 12, 13, 10.1038/nrneph.2015.175 Sourris, 2009, Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets, Curr Drug Targets, 10, 42, 10.2174/138945009787122905 Nguyen, 2006, Macrophage accumulation in human progressive diabetic nephropathy, Nephrology (Carlton), 11, 226, 10.1111/j.1440-1797.2006.00576.x Flyvbjerg, 2017, The role of the complement system in diabetic nephropathy, Nat Rev Nephrol, 13, 311, 10.1038/nrneph.2017.31 Brosius, 2016, JAK inhibition in the treatment of diabetic kidney disease, Diabetologia, 59, 1624, 10.1007/s00125-016-4021-5 Anders, 2013, The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease, Kidney Int, 83, 1010, 10.1038/ki.2012.440 Giacchetti, 2005, The renin-angiotensin-aldosterone system, glucose metabolism and diabetes, Trends Endocrinol Metab, 16, 120, 10.1016/j.tem.2005.02.003 Toma, 2008, Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney, J Clin Invest, 118, 2526 Vegter, 2012, Sodium intake, ACE inhibition, and progression to ESRD., J Am Soc Nephrol, 23, 165, 10.1681/ASN.2011040430 Gurley, 2007, The renin-angiotensin system and diabetic nephropathy, Semin Nephrol, 27, 144, 10.1016/j.semnephrol.2007.01.009 He, 2013, Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease, Clin Exp Nephrol, 17, 488, 10.1007/s10157-013-0781-0 Ritz, 2009, Aldosterone, a vasculotoxic agent–novel functions for an old hormone, Nephrol Dial Transplant, 24, 2302, 10.1093/ndt/gfp206 Portela, 2010, Epigenetic modifications and human disease, Nat Biotechnol, 28, 1057, 10.1038/nbt.1685 Horsburgh, 2015, Exercise and inflammation-related epigenetic modifications: focus on DNA methylation, Exerc Immunol Rev, 21, 26 Bell, 2010, Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus, BMC Med Genomics, 3, 33, 10.1186/1755-8794-3-33 Bechtel, 2010, Methylation determines fibroblast activation and fibrogenesis in the kidney, Nat Med, 16, 544, 10.1038/nm.2135 Bartel, 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002 Kato, 2007, MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors, Proc Natl Acad Sci U S A, 104, 3432, 10.1073/pnas.0611192104 Kato, 2011, A microRNA circuit mediates transforming growth factor-beta1 autoregulation in renal glomerular mesangial cells, Kidney Int, 80, 358, 10.1038/ki.2011.43 Deshpande, 2013, Transforming growth factor-beta-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy, Diabetes, 62, 3151, 10.2337/db13-0305 Kato, 2013, TGF-beta induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy, Sci Signal, 6, ra43, 10.1126/scisignal.2003389 Sun, 2010, Epigenetic histone methylation modulates fibrotic gene expression, J Am Soc Nephrol, 21, 2069, 10.1681/ASN.2010060633 Hayes, 2014, The Nrf2 regulatory network provides an interface between redox and intermediary metabolism, Trends Biochem Sci, 39, 199, 10.1016/j.tibs.2014.02.002 Yoh, 2008, Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice, Genes Cells, 13, 1159 Jiang, 2010, The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy, Diabetes, 59, 850, 10.2337/db09-1342 Pergola, 2011, Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD, Am J Nephrol, 33, 469, 10.1159/000327599 Xu, 2013, Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a novel therapeutic target for diabetic complications, J Int Med Res, 41, 13, 10.1177/0300060513477004 Kim, 2012, The role of autophagy in unilateral ureteral obstruction rat model, Nephrology (Carlton), 17, 148, 10.1111/j.1440-1797.2011.01541.x Zhu, 2013, After the banquet: mitochondrial biogenesis, mitophagy, and cell survival, Autophagy, 9, 1663, 10.4161/auto.24135 Geng, 2008, The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. 'Protein modifications: beyond the usual suspects' review series, EMBO Rep, 9, 859, 10.1038/embor.2008.163 Liu, 2016, beta-Arrestins promote podocyte injury by inhibition of autophagy in diabetic nephropathy, Cell Death Dis, 7, 10.1038/cddis.2016.89 Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 Engelman, 2006, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nat Rev Genet, 7, 606, 10.1038/nrg1879 Sarbassov, 2005, Growing roles for the mTOR pathway, Curr Opin Cell Biol, 17, 596, 10.1016/j.ceb.2005.09.009 Zhang, 2009, AMPK: an emerging drug target for diabetes and the metabolic syndrome, Cell Metab, 9, 407, 10.1016/j.cmet.2009.03.012 Jin, 2017, Berberine enhances the AMPK activation and autophagy and mitigates high glucose-induced apoptosis of mouse podocytes, Eur J Pharmacol, 794, 106, 10.1016/j.ejphar.2016.11.037 Giacco, 2010, Oxidative stress and diabetic complications, Circ Res, 107, 1058, 10.1161/CIRCRESAHA.110.223545 Du, 2003, Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells, J Clin Invest, 112, 1049, 10.1172/JCI18127 Sharma, 2015, Mitochondrial hormesis and diabetic complications, Diabetes, 64, 663, 10.2337/db14-0874 Gordon, 2015, Targeting skeletal muscle mitochondria to prevent type 2 diabetes in youth, Biochem Cell Biol, 93, 452, 10.1139/bcb-2015-0012 Perkovic, 2013, Intensive glucose control improves kidney outcomes in patients with type 2 diabetes, Kidney Int, 83, 517, 10.1038/ki.2012.401 2014, Standards of medical care in diabetes–2014, Diabetes Care, 37, S14 Andresdottir, 2014, Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors, Diabetes Care, 37, 1660, 10.2337/dc13-2036 Wang, 1993, Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes, Lancet, 341, 1306, 10.1016/0140-6736(93)90816-Y Group DER, 2011, Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes, N Engl J Med, 365, 2366, 10.1056/NEJMoa1111732 Ahmad, 1997, Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria, Diabetes Care, 20, 1576, 10.2337/diacare.20.10.1576 Huang, 2017, Factors associated with diabetic nephropathy in children, adolescents, and adults with type 1 diabetes, J Formos Med Assoc, 116, 924, 10.1016/j.jfma.2017.09.015 Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med, 348, 383, 10.1056/NEJMoa021778 Breyer, 1996, Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group, Kidney Int, 50, 1651, 10.1038/ki.1996.481 2012, KDOQI Clinical practice guideline for diabetes and CKD: 2012 update, Am J Kidney Dis, 60, 850, 10.1053/j.ajkd.2012.07.005 Zatz, 1986, Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension, J Clin Invest, 77, 1925, 10.1172/JCI112521 Fujihara, 1992, Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy, Diabetes, 41, 286, 10.2337/diab.41.3.286 1998, Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group, BMJ, 317, 713, 10.1136/bmj.317.7160.713 Ali, 2013, Achievement of goals in US diabetes care, 1999–2010, N Engl J Med, 368, 1613, 10.1056/NEJMsa1213829 Palmer, 2004, Diabetes Care, 27, 1897, 10.2337/diacare.27.8.1897 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 Mathiesen, 1997, Stable glomerular filtration rate in normotensive IDDM patients with stable microalbuminuria: a 5-year prospective study, Diabetes Care, 20, 286, 10.2337/diacare.20.3.286 Lacourcière, 2000, Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy, Kidney Int, 58, 762, 10.1046/j.1523-1755.2000.00224.x Chen, 2015, Multidisciplinary care program for advanced chronic kidney disease: reduces renal replacement and medical costs, Am J Med, 128, 68, 10.1016/j.amjmed.2014.07.042 Chen, 2016, Proteinuria as a therapeutic target in advanced chronic kidney disease: a retrospective multicenter cohort study, Sci Rep, 6, 26539, 10.1038/srep26539 Jacobsen, 2003, Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy, Kidney Int, 63, 1874, 10.1046/j.1523-1755.2003.00940.x Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2 Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154 Sen, 2014, Renin inhibitors in diabetes and hypertension: an update, EXCLI J, 13, 1111 Taler, 2013, KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD, Am J Kidney Dis, 62, 201, 10.1053/j.ajkd.2013.03.018 de Zeeuw, 2015, Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial, Lancet Diabetes Endocrinol, 3, 181, 10.1016/S2213-8587(14)70246-3 Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002 Andrassy, 2013, Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease', Kidney Int, 84, 622, 10.1038/ki.2013.243 Esnault, 2005, Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents, J Am Soc Nephrol, 16, 474, 10.1681/ASN.2004060505 Tanasescu, 2003, Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes, Circulation, 107, 2435, 10.1161/01.CIR.0000066906.11109.1F Salem, 2010, Is exercise a therapeutic tool for improvement of cardiovascular risk factors in adolescents with type 1 diabetes mellitus? A randomised controlled trial, Diabetol Metab Syndr, 2, 47, 10.1186/1758-5996-2-47 Tufescu, 2008, Combination of exercise and losartan enhances renoprotective and peripheral effects in spontaneously type 2 diabetes mellitus rats with nephropathy, J Hypertens, 26, 312, 10.1097/HJH.0b013e3282f2450b Zinman, 2003, Physical activity/exercise and diabetes mellitus, Diabetes Care, 26, S73 Friedman, 2013, Short-term changes after a weight reduction intervention in advanced diabetic nephropathy, Clin J Am Soc Nephrol, 8, 1892, 10.2215/CJN.04010413 Heneghan, 2013, Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up, Surg Obesity Relat Dis, 9, 7, 10.1016/j.soard.2012.08.016 Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920 Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925 Imamura, 2013, The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients, Tohoku J Exp Med, 231, 57, 10.1620/tjem.231.57 von Scholten, 2015, Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes, J Diabetes Complications, 29, 670, 10.1016/j.jdiacomp.2015.04.004 Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 375, 311, 10.1056/NEJMoa1603827 Mann, 2017, Liraglutide and renal outcomes in type 2 diabetes, N Engl J Med, 377, 839, 10.1056/NEJMoa1616011 Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 375, 1834, 10.1056/NEJMoa1607141 Groop, 2013, Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction, Diabetes Care, 36, 3460, 10.2337/dc13-0323 Mosenzon, 2017, Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial, Diabetes Care, 40, 69, 10.2337/dc16-0621 Bakris, 2006, Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria, J Hypertens, 24, 2047, 10.1097/01.hjh.0000244955.39491.88 Bakris, 2003, Rosiglitazone reduces urinary albumin excretion in type II diabetes, J Hum Hypertens, 17, 7, 10.1038/sj.jhh.1001444 Lin, 2005, Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor, J Am Soc Nephrol, 16, 2702, 10.1681/ASN.2005040435 Lin, 2004, Pentoxifylline: a potential therapy for chronic kidney disease, Nephrology (Carlton), 9, 198, 10.1111/j.1440-1797.2004.00267.x Chen, 2014, Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease, J Formos Med Assoc, 113, 219, 10.1016/j.jfma.2014.01.002 Navarro-Gonzalez, 2015, Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial, J Am Soc Nephrol, 26, 220, 10.1681/ASN.2014010012 Lai, 2016, Pentoxifylline: evidence strong enough for renoprotection?, J Formos Med Assoc, 115, 591, 10.1016/j.jfma.2015.12.010 Li, 2002, 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system, J Clin Invest, 110, 229, 10.1172/JCI0215219 Zhang, 2008, Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase, Proc Natl Acad Sci U S A, 105, 15896, 10.1073/pnas.0803751105 Agarwal, 2005, Antiproteinuric effect of oral paricalcitol in chronic kidney disease, Kidney Int, 68, 2823, 10.1111/j.1523-1755.2005.00755.x de Zeeuw, 2010, Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial, Lancet, 376, 1543, 10.1016/S0140-6736(10)61032-X Williams, 2007, Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy, Am J Nephrol, 27, 605, 10.1159/000108104 House, 2010, Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial, JAMA, 303, 1603, 10.1001/jama.2010.490 Mann, 2010, Avosentan for overt diabetic nephropathy, J Am Soc Nephrol, 21, 527, 10.1681/ASN.2009060593 Tuttle, 2005, The effect of ruboxistaurin on nephropathy in type 2 diabetes, Diabetes Care, 28, 2686, 10.2337/diacare.28.11.2686 Tuttle, 2007, Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease, Clin J Am Soc Nephrol, 2, 631, 10.2215/CJN.00840207 Li, 2015, Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review, Drug Des Devel Ther, 9, 6275 Sharma, 2011, Pirfenidone for diabetic nephropathy, J Am Soc Nephrol, 22, 1144, 10.1681/ASN.2010101049 Li, 2017, Pirfenidone suppresses MAPK signaling pathway to reverse epithelial-mesenchymal transition and renal fibrosis, Nephrology (Carlton), 22, 589, 10.1111/nep.12831 Pergola, 2011, Bardoxolone methyl and kidney function in CKD with type 2 diabetes, N Engl J Med, 365, 327, 10.1056/NEJMoa1105351 de Zeeuw, 2013, Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease, N Engl J Med, 369, 2492, 10.1056/NEJMoa1306033 Chrysostomou, 2001, Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease, N Engl J Med, 345, 925, 10.1056/NEJM200109203451215 Lazich, 2014, Prediction and management of hyperkalemia across the spectrum of chronic kidney disease, Semin Nephrol, 34, 333, 10.1016/j.semnephrol.2014.04.008 Bakris, 2015, Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial, JAMA, 314, 884, 10.1001/jama.2015.10081